Business Context and Reporting Period
Kura Oncology, Inc. filed this Form 8-K on April 27, 2016, to report the entry into a material definitive loan and security agreement. The Company is a biopharmaceutical entity focused on developing oncology treatments, specifically mentioning the advancement of its candidate KO-947.
Key Financial Metrics and Debt Structure
The filing details a new credit facility with Oxford Finance LLC and Silicon Valley Bank. Key terms include:
- Total Facility Size: Up to $20.0 million in term loans.
- Initial Draw (Term A Loan): $7.5 million borrowed immediately upon closing.
- Optional Draw (Term B Loan): Up to an additional $12.5 million available between December 31, 2016, and May 1, 2017, contingent on KO-947 advancing to Phase 1 clinical trials.
- Interest Rate: Fixed at the greater of 7.75% or Prime Rate + 4.25%.
- Maturity Date: November 1, 2020.
- Repayment Terms: Interest-only through June 1, 2018, followed by 30 equal monthly principal and interest payments.
- Final Payment Fee: 7.50% of drawn amounts due at maturity or prepayment.
- Prepayment Fees: 3.00% (Year 1), 2.00% (Year 2), or 1.00% (Year 3+).
- Unused Fee: 2.00% on any portion of the $20.0 million facility not drawn by May 1, 2017.
The filing does not provide current revenue, profit, cash flow, or liquidity metrics beyond the new debt obligation.
Material Changes and Equity Issuance
In connection with the loan agreement, the Company issued unregistered warrants to the lenders:
- Initial Warrants: 67,976 shares exercisable immediately at $3.31 per share.
- Additional Warrants: If the Term B Loan is drawn, additional warrants will be issued equal to 3.00% of the loan amount divided by the lower of the 10-day average closing price or the closing price prior to funding.
- Security Interest: The Company granted a first priority security interest in substantially all current and future assets, excluding intellectual property.
Guidance, Risks, and Covenants
The agreement includes significant restrictive covenants and risks:
- Dividend Restriction: The Company is prohibited from paying dividends or making distributions on capital stock, subject to limited exceptions.
- Operational Milestone: Access to the remaining $12.5 million is strictly conditioned on the successful advancement of KO-947 into Phase 1 trials.
- Default Triggers: Events of default include failure to satisfy payment obligations, breach of covenants, or a material adverse change, which could accelerate all principal and interest.
- Intellectual Property: The Company agreed not to encumber its intellectual property assets except as permitted by the Agreement.
Investor Verification Checklist
- Verify the current status of the KO-947 clinical trial to assess the likelihood of drawing the remaining $12.5 million.
- Review the Company's cash burn rate to determine if the $7.5 million initial draw is sufficient to reach the next funding milestone.
- Calculate the total cost of capital including the 7.50% final payment fee and potential unused fees.
- Assess the dilution impact of the initial 67,976 warrants and potential future warrants.
- Confirm compliance with affirmative covenants regarding financial statement delivery and insurance maintenance.